Regeneron Pharmaceuticals Inc (REGN34)

B3


	Symbol		Exchange		Currency
	REGN34		B3		BRL	Delayed
	REGN		NASDAQ		USD	Real-time
	1REGN		Milan		EUR	Real-time
	REGN		TradeGate		EUR	Delayed
	REGN		Frankfurt		EUR	Delayed
	REGN		Vienna		EUR	Real-time
	REGN		Lima		USD	Delayed

Currency in BRL

Disclaimer

91.08

0.00(0.00%)

Closed07/10

Fair Value

Day's Range

91.00

91.62

52 wk Range

62.10

111.72

REGN34 Income Statement

Featured here, the Income Statement (earnings report) for Regeneron Pharmaceuticals Inc, showing the company's financial performance from operating and non operating activities such as revenue, expenses and income for the last 4 periods (either quarterly or annually).

Advanced Income Statement

Period Ending:

2014

31/12

2015

31/12

2016

31/12

2017

31/12

2018

31/12

2019

31/12

2020

31/12

2021

31/12

2022

31/12

2023

31/12

Total Revenues

6,557.6

8,497.1

16,071.7

12,172.9

13,117.2

Total Revenues Growth

+27.44%

+29.58%

+89.14%

-24.26%

+7.76%

Cost Of Revenues

3,215.1

3,766.9

5,297.6

5,152.9

6,254.8

Gross Profit

3,342.5

4,730.2

10,774.1

7,020

6,862.4

Gross Profit Growth

+2.55%

+41.52%

+127.77%

-34.84%

-2.25%

Gross Profit Margin %

50.97%

55.67%

67.04%

57.67%

52.32%

Other Operating Expenses, Total

1,132.7

1,065.6

1,779.3

2,026

2,629.2

	Other Operating Expenses, Total Growth
	R&D Expenses
	Selling General & Admin Expenses
	Other Operating Expenses

aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	+56.26%	-5.92%	+66.98%	+13.87%	+29.77%
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-	-	-	-	-
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	1,341.9	1,346	1,824.9	2,115.9	2,631.3
aa.aa	aa.aa	aa.aa	aa.aa	aa.aa	-209.2	-280.4	-45.6	-89.9	-2.1

Operating Income

2,209.8

3,664.6

8,994.8

4,994

4,233.2

Operating Income Growth

-12.81%

+65.83%

+145.45%

-44.48%

-15.23%

EBIT Margin %

33.7%

43.13%

55.97%

41.03%

32.27%

Net Interest Expenses

-30.2

18.5

-11.5

100.7

422.9

Net Interest Expenses Growth

-7.09%

+161.26%

-162.16%

+975.65%

+319.96%

Interest Expense, Total

-30.2

-56.9

-57.3

-59.4

-73

Interest And Investment Income

-

75.4

45.8

160.1

495.9

Other Non Operating Expenses, Total

131.2

19.3

4.4

59

-32.9

EBT, Excl. Unusual Items

2,310.8

3,702.4

8,987.7

5,153.7

4,623.2

Gain (Loss) On Sale Of Assets

-

-

-

-

-

Other Unusual Items, Total

-

-88

-48

-255.1

-186.1

EBT, Incl. Unusual Items

2,429.1

3,810.4

9,325.8

4,858.8

4,199.3

EBT, Incl. Unusual Items Growth

-4.87%

+56.86%

+144.75%

-47.9%

-13.57%

EBT, Incl. Unusual Items Margin

37.04%

44.84%

58.03%

39.91%

32.01%

Income Tax Expense

313.3

297.2

1,250.5

520.4

245.7

Net Income to Company

2,115.8

3,513.2

8,075.3

4,338.4

3,953.6

Minority Interest

-

-

-

-

-

Net Income

2,115.8

3,513.2

8,075.3

4,338.4

3,953.6

Net Income Growth

-13.44%

+66.05%

+129.86%

-46.28%

-8.87%

Net Income Margin %

32.26%

41.35%

50.25%

35.64%

30.14%

Preferred Dividend and Other Adjustments

-

-

-

-

-

Net Income to Common Excl. Extra Items

2,115.8

3,513.2

8,075.3

4,338.4

3,953.6

Basic EPS - Continuing Operations

19.38

32.65

76.4

40.51

37.05

Basic EPS - Continuing Operations Growth

-14.47%

+68.52%

+133.99%

-46.98%

-8.53%

Diluted EPS - Continuing Operations

18.46

30.52

71.97

38.22

34.77

Diluted EPS - Continuing Operations Growth

-13.29%

+65.33%

+135.81%

-46.89%

-9.03%

Basic Weighted Average Shares Outstanding

109.2

107.6

105.7

107.1

106.7

Diluted Weighted Average Shares Outstanding

114.6

115.1

112.2

113.5

113.7

Dividend Per Share

-

-

-

-

-

Dividend Per Share Growth

-

-

-

-

-

EBITDA

2,420.1

3,900.5

9,281

5,335.4

4,654.2

EBITDA Growth

-9.79%

+61.17%

+137.94%

-42.51%

-12.77%

EBITDA Margin %